212 related articles for article (PubMed ID: 10170246)
21. Precipitating factors for pharmaceutical firms.
McCarthy R
State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
[No Abstract] [Full Text] [Related]
22. Perspectives. Drug utilization review: apocalypse when?
Ault A
Faulkner Grays Med Health; 1992 Feb; 46(8):suppl 4 p.. PubMed ID: 10116064
[No Abstract] [Full Text] [Related]
23. FDA considers effects of managed care marketplace on drug promotional practices.
Wechsler J
Formulary; 1995 Dec; 30(12):840-1. PubMed ID: 10153083
[No Abstract] [Full Text] [Related]
24. Pharmaceuticals and medical devices: cost savings.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
[No Abstract] [Full Text] [Related]
25. Forecasting the future.
Tecnologica; 1999 Dec; ():1, 3-6, 14-5. PubMed ID: 10848110
[No Abstract] [Full Text] [Related]
26. Regulatory and legislative challenges facing managed care.
Giaquinta D
Manag Care Interface; 2000 Jul; 13(7):47-9. PubMed ID: 11183928
[No Abstract] [Full Text] [Related]
27. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
[No Abstract] [Full Text] [Related]
28. The case for a value-based formulary: striving for total lowest net cost.
Weart W; Bauman GR
Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
[TBL] [Abstract][Full Text] [Related]
29. Pharmacotherapy: strategies to control drug costs in managed care.
Monane M; Nagle B; Kelly MA
Geriatrics; 1998 Sep; 53(9):51-4, 63; quiz 64. PubMed ID: 9745626
[TBL] [Abstract][Full Text] [Related]
30. [New medical care models in the USA and their effect on the therapeutic freedom of the American physician].
Fetscher S
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):644-8. PubMed ID: 9527461
[TBL] [Abstract][Full Text] [Related]
31. Decrease hassles and costs by integrating your plans' formularies.
Domino FJ; Baldor RA
Fam Pract Manag; 1998; 5(10):27-30. PubMed ID: 10344926
[No Abstract] [Full Text] [Related]
32. The devil is in the details: Managed care and the unforeseen costs of utilization review as a cost containment mechanism.
Saunier B
Issues Law Med; 2011; 27(1):21-48. PubMed ID: 21919314
[TBL] [Abstract][Full Text] [Related]
33. Impact of formularies on clinical innovation.
Goodwin FK
J Clin Psychiatry; 2003; 64 Suppl 17():11-4. PubMed ID: 14680421
[TBL] [Abstract][Full Text] [Related]
34. Study examines weapons in fight to control drug costs.
Capitation Rates Data; 2001 Apr; 6(4):39-42. PubMed ID: 11330005
[No Abstract] [Full Text] [Related]
35. Will external review mandates revolutionize managed care?
Lewis A
Manag Care Interface; 2000 Oct; 13(10):64, 66. PubMed ID: 11155644
[No Abstract] [Full Text] [Related]
36. Managed care guidelines for the economic evaluation of pharmaceuticals.
Langley PC; Martin RE
Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
[TBL] [Abstract][Full Text] [Related]
37. Escalating need for comparative analysis of drugs within a therapeutic class.
Giaquinta D
Manag Care Interface; 2003 Oct; 16(10):32-4. PubMed ID: 14606258
[No Abstract] [Full Text] [Related]
38. To cut costs, risky drug use.
Consum Rep; 2011 Nov; 76(11):9. PubMed ID: 22022754
[No Abstract] [Full Text] [Related]
39. Focus on the patent cliff to maximize generic savings.
Cahn L
Manag Care; 2012 Nov; 21(11):28-32. PubMed ID: 23236715
[No Abstract] [Full Text] [Related]
40. Medication restrictions: feeling the side effects.
Fitzpatrick C
Behav Healthc Tomorrow; 2001 Oct; 10(5):14-7, 39-40. PubMed ID: 11594068
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
